Skip to main content

Advertisement

Log in

Omalizumab in the treatment of eosinophilic esophagitis and food allergy

  • Short Report
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Omalizumab is currently used in severe asthma and has been tried in other allergic disorders. The authors report two patients with multiple food allergies and eosinophilic esophagitis on a very restrictive diet who have been treated with omalizumab, in order to improve food intolerance—the major distressing factor in their lives. The patients significantly improved in the reported symptoms. However, no improvement was seen regarding esophageal endoscopy and histology. Given the poor histological and endoscopy response, eosinophilic esophagitis persistence is unlikely to be IgE dependent. Omalizumab may improve the quality of life of patients with severe food allergy by improving symptoms, but it does not appear to change endoscopic and histological features of eosinophilic esophagitis in a short follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Alpan O (2009) Identifying responders to Xolair (omalizumab) using eosinophilic esophagitis as a disease model. ClinicalTrials.gov identifier: NCT01040598. Available via http://clinicaltrials.gov. Accessed 2 April 2011

  2. Fang JC (2005) A pilot study of the treatment of eosinophilic esophagitis with omalizumab. ClinicalTrials.gov identifier: NCT00123630. Available via http://clinicaltrials.gov. Accessed 2 April 2011

  3. Menzella F, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L (2009) Omalizumab: when the non-responder is a late-responder. Eur Ann Allergy Clin Immunol 41(5):155–9

    PubMed  CAS  Google Scholar 

  4. Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW, Klaustermeyer W (2010) Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 31(1):76–83

    Article  PubMed  Google Scholar 

  5. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, Filipovich AH, Assa'ad AH, Rothenberg ME (2006) Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118(6):1312–9

    Article  PubMed  CAS  Google Scholar 

  6. Stone KD, Prussin C (2008) Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases. Clin Exp Allergy 38(12):1858–65

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ruben Rocha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rocha, R., Vitor, A.B., Trindade, E. et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 170, 1471–1474 (2011). https://doi.org/10.1007/s00431-011-1540-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-011-1540-4

Keywords

Navigation